3-phenyl-3-(pyrrol-1-yl)propanoic acid | 75391-17-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 3-phenyl-3-(pyrrol-1-yl)propanoic acid
• 英文别名: 3-phenyl-3-(1H-pyrrol-1-yl)propanoic acid；3-phenyl-3-pyrrol-1-ylpropanoic acid
• CAS: 75391-17-2
• 化学式: C₁₃H₁₃NO₂
• mdl: MFCD03768199
• 分子量: 215.252
• InChiKey: GLJWRQSFZOJOLE-UHFFFAOYSA-N

物化性质

• 熔点：
  120-122 °C(Solv: ethyl ether (60-29-7))
• 沸点：
  360.3±30.0 °C(Predicted)
• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.153
• 拓扑面积：
  42.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-phenyl-3-(pyrrol-1-yl)propanoic acid 在 三光气 、 sodium hydroxide 作用下， 以 甲醇 、 水 、 甲苯 为溶剂， 反应 121.5h， 生成 (2E)-2-benzylidene-3-phenyl-3H-pyrrolizin-1-one
  参考文献：
  名称：

  具有多效活性的新型亚苄基苯基吡咯烷酮可能在阿尔茨海默氏病的治疗中有用

  摘要：

  这项工作描述了新型的亚苄基苯基吡咯烷酮作为潜在的抗氧化剂，金属螯合或淀粉样β（βA）聚集抑制剂的合成和生物学评估。一些衍生物在一些评估中表现出令人感兴趣的结果，并显示为有价值的多靶标配体，对阿尔茨海默氏病具有潜在的治疗意义。其中，化合物29特别显示为有价值的自由基和NO清除剂，Cu（II）和Fe（II）螯合剂，并具有中等的βA聚集抑制性能。这些活动与良好的预测生物利用度和缺乏细胞毒性有关，将其设计为进一步体内研究的有希望的手段。

  DOI：

  10.1016/j.ejmech.2016.03.023
• 作为产物：
  描述：

  亚苯甲基丙二酸二乙酯 在 氢氧化钾 作用下， 以 乙醇 、 水 为溶剂， 反应 24.0h， 生成 3-phenyl-3-(pyrrol-1-yl)propanoic acid
  参考文献：
  名称：

  Neidlein, Richard; Jeromin, Guenther, Journal of Chemical Research, Miniprint, 1980, # 7, p. 3078 - 3089

  摘要：

  DOI：

文献信息

• [EN] FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY<br/>[FR] DÉRIVÉS DE [1,2,4]THIADIAZINE FUSIONNÉS AGISSANT EN TANT QU'INHIBITEURS DE KAT DE LA FAMILLE DES MYST
  申请人：CTXT PTY LTD

  公开号：WO2019043139A1

  公开（公告）日：2019-03-07

  A compound of formula (I): which inhibits the activity of one or more KATs of the MYST family, i.e., TIP60, KAT6B, MOZ, HBO1 and MOF.

  一种化合物的化学式（I）：抑制MYST家族中一个或多个KATs的活性，即TIP60、KAT6B、MOZ、HBO1和MOF。
• (2-Alkyl-3-pyridyl)methylpiperazine derivatives as PAF antagonists
  申请人：J. URIACH & CIA. S.A.

  公开号：EP0528172A1

  公开（公告）日：1993-02-24

  The present invention relates to new (2-alkyl-3-pyridyl)methylpiperazine derivatives of general formula I: wherein R¹, R² and Z are as defined in Claim 1. The invention also relates to processes for their preparation and to pharmaceutical compositions containing them. These compounds are potent, orally active PAF antagonists and, consequently, they are useful in the treatment of the diseases in which this substance is involved.

  本发明涉及一般式I的新(2-烷基-3-吡啶基)甲基哌嗪衍生物，其中R¹，R²和Z如权利要求1所定义。该发明还涉及它们的制备方法以及含有它们的药物组合物。这些化合物是有效的口服PAF拮抗剂，因此它们在治疗涉及该物质的疾病中很有用。
• Synthesis and preliminary behavioural evaluation in mice of new 3-aryl-3-pyrrol-1-ylpropanamides, analogues of FGIN-1–27 and FGIN-1–43
  作者：J Guillon、M Boulouard、V Lelong、P Dallemagne、S Rault、C Jarry

  DOI：10.1211/0022357011777945

  日期：2010.2.18

  The 2-aryl-3-indoleacetamides FGIN-1–27 and FGIN-1–43 have already been characterized in-vitro as potent and specific ligands for the mitochondrial DBI receptor. This affinity was associated with psychotropic properties in several rodent behavioural tasks (in particular anxiolytic action) via enhancement of GABA transmission through neurosteroid production. The synthesis of new 3-aryl-3-pyrrol-1-ylpropanamides 1a-i, analogues of FGIN-1–27 and FGIN-1–43, is described in four steps starting from the corresponding arylaldehydes. Preliminary evaluation of these compounds in behavioural studies (spontaneous locomotor activity and anxiolytic activity) in mice was also undertaken.

  摘要：2-芳基-3-吲哚乙酰胺FGIN-1-27和FGIN-1-43已在体外被表征为线粒体DBI受体的有效和特异配体。这种亲和力与在几种啮齿动物行为任务中（尤其是抗焦虑作用）的精神药理特性相关联，通过促进GABA传递和神经类固醇的产生。从相应的芳基醛开始，描述了新的3-芳基-3-吡咯-1-基丙酰胺1a-i的合成过程，这些化合物是FGIN-1-27和FGIN-1-43的类似物。此外，还进行了对这些化合物在小鼠行为研究（自发性运动活动和抗焦虑活性）中的初步评估。
• Synthesis and structure-activity relationships of 1-acyl-4-((2-methyl-3-pyridyl)cyanomethyl)piperazines as PAF antagonists
  作者：Elena Carceller、Manuel Merlos、Marta Giral、Carmen Almansa、Javier Bartroli、Julian Garcia-Rafanell、Javier Forn

  DOI：10.1021/jm00072a019

  日期：1993.10

  A second generation of (cyanomethyl)piperazines, 1-acyl-4-((2-methyl-3-pyridyl)cyanomethyl)-piperazines, with increased oral activity was prepared and evaluated in vitro in a PAF-induced platelet aggregation assay (PAG) and in vivo in a PAF-induced hypotension test in normotensive rats (HYP). Oral activity was ascertained through a PAF-induced mortality test in mice (MOR). Attachment of a methyl group at position 2 of our earlier pyridine derivatives resulted in an improvement of 1 order of magnitude or greater in the ID50 of the oral test. Three different types of acyl substituents of similar potency emerge from this work: N-(diphenylmethylamino)acetyl, 3-substituted 3-hydroxy-3-phenylpropionyl, and N-substituted 3-amino-3-phenylpropionyl groups. The most interesting compounds, 26 (UR-12460, PAG IC50 = 0.040 muM, HYP, ID50 = 0.021 mg/kg iv, MOR, ID50 = 0.30 mg/kg po) and 58 (UR- 12519, PAG IC50 = 0.041 muM, HYP, ID50 = 0.015 mg/kg iv, MOR, ID50 = 0.044 mg/kg po), compare favorably with WEB-2086. Compounds 26 and 58 were also tested in active anaphylactic shock (AAS) and endotoxin-induced mortality (EIM) tests. On the basis of these data, compounds 26 and 58 have been selected for further pharmacological development.
• Synthesis and CNS Activity of New 3-Amino-3-arylpropionic Acid Derivatives
  作者：O. Renault、J. Guillon、C. Huard、H. Miel、S. Stiebing、S. Le Bourn、M. Boulouard、P. Dallemagne、S. Rault

  DOI：10.1211/146080899128734631

  日期：1999.3.1